PARP1 and ovarian carcinoma: Specifically, immunotherapy as adjuvant therapy, combined with chemotherapy, radiotherapy, use of anti-angiogenic drugs and PARP inhibitors, can significantly improve the efficiency of ovarian cancer treatment [100].